Literature DB >> 30333875

Antitumorigenic effect of damnacanthal on melanoma cell viability through p53 and NF-κB/caspase-3 signaling pathways.

Xin Zhang1, Ping Fang2, Zigang Zhao1, Xiangyu Ding1, Fang Xie1, Yilin Wang1, Chengxin Li1.   

Abstract

Melanoma is highly malignant, particularly prone to metastasizing to the skin. The incidence of melanoma varies markedly between countries, and is relatively low in China. The aim of the present study was to investigate the antitumorigenic effect of damnacanthal on melanoma cells, and its molecular mechanism. MUM-2B cells were treated with 0-20 µM damnacanthal for 12, 24 and 48 h. In vitro, it was demonstrated that damnacanthal inhibited proliferation and promoted apoptosis of melanoma cells in a dose- and time-dependent manner. Damnacanthal treatment increased caspase-3/8 and 9 activity, and promoted B-cell lymphoma 2-associated X protein, tumor protein p53 (p53) and p21 protein expression levels in melanoma cells. Damnacanthal treatment also resulted in downregulated nuclear factor-κB (NF-κB), cyclin D and cyclin E protein expression in melanoma cells. In conclusion, the results of the present study demonstrated that the antitumorigenic activity of damnacanthal on melanoma cells is executed via the p53/p21 and NF-κB/cyclin/ caspase-3 signaling pathways.

Entities:  

Keywords:  damnacanthal; melanoma; nuclear factor-κB; tumor protein p53

Year:  2018        PMID: 30333875      PMCID: PMC6176422          DOI: 10.3892/ol.2018.9379

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

1.  Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.

Authors:  Pier F Ferrucci; Ida Minchella; Massimo Mosconi; Sara Gandini; Francesco Verrecchia; Emilia Cocorocchio; Claudia Passoni; Chiara Pari; Alessandro Testori; Paola Coco; Elisabetta Munzone
Journal:  Melanoma Res       Date:  2015-06       Impact factor: 3.599

2.  TP 53 polymorphisms and melanoma: A meta-analysis.

Authors:  Ting He; Jinhu Wu; Yong Chen; Junzhi Zhang
Journal:  J Cancer Res Ther       Date:  2015 Apr-Jun       Impact factor: 1.805

3.  Damnacanthal and its nanoformulation exhibit anti-cancer activity via cyclin D1 down-regulation.

Authors:  Pakin Sukamporn; Pleumchitt Rojanapanthu; Gabriel Silva; Xiaobo Zhang; Wandee Gritsanapan; Seung Joon Baek
Journal:  Life Sci       Date:  2016-03-24       Impact factor: 5.037

4.  Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.

Authors:  Bin Lian; Lu Si; Chuanliang Cui; Zhihong Chi; Xinan Sheng; Lili Mao; Siming Li; Yan Kong; Bixia Tang; Jun Guo
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

5.  Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.

Authors:  Kelly M McMasters; Michael E Egger; Michael J Edwards; Merrick I Ross; Douglas S Reintgen; R Dirk Noyes; Robert C G Martin; James S Goydos; Peter D Beitsch; Marshall M Urist; Stephan Ariyan; Jeffrey J Sussman; B Scott Davidson; Jeffrey E Gershenwald; Lee J Hagendoorn; Arnold J Stromberg; Charles R Scoggins
Journal:  J Clin Oncol       Date:  2016-02-08       Impact factor: 44.544

6.  Dimethylfumarate inhibits melanoma cell proliferation via p21 and p53 induction and bcl-2 and cyclin B1 downregulation.

Authors:  Irina Kaluzki; Igor Hrgovic; Tsige Hailemariam-Jahn; Monika Doll; Johannes Kleemann; Eva Maria Valesky; Stefan Kippenberger; Roland Kaufmann; Nadja Zoeller; Markus Meissner
Journal:  Tumour Biol       Date:  2016-07-29

7.  Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses.

Authors:  Anna Vilgelm; Ann Richmond
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

Review 8.  Damnacanthal: a promising compound as a medicinal anthraquinone.

Authors:  Nadiah Abu; Norlaily Mohd Ali; Wan Yong Ho; Swee Keong Yeap; Muhammad Yusran Abdul Aziz; Noorjahan Banu Alitheen
Journal:  Anticancer Agents Med Chem       Date:  2014-06       Impact factor: 2.505

9.  NF-κB in cancer: a matter of life and death.

Authors:  Bharat B Aggarwal; Bokyung Sung
Journal:  Cancer Discov       Date:  2011-11       Impact factor: 39.397

10.  Melanoma-associated cancer-testis antigen 16 (CT16) regulates the expression of apoptotic and antiapoptotic genes and promotes cell survival.

Authors:  Camilla Nylund; Pekka Rappu; Eveliina Pakula; Aleksi Heino; Laura Laato; Laura L Elo; Pia Vihinen; Seppo Pyrhönen; Gethin R Owen; Hannu Larjava; Markku Kallajoki; Jyrki Heino
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.